TAK (Takeda Pharmaceutical Co) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TAK Takeda Pharmaceutical Co Ltd TAK
72 GF Score
Price $18.91
GF Value $14.10
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Takeda Pharmaceutical Co Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Takeda Pharmaceutical Co  (NYSE:TAK) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Takeda Pharmaceutical Co Cyclically Adjusted PS Ratio Related Terms


Takeda Pharmaceutical Co Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takeda Pharmaceutical Co Cyclically Adjusted PS Ratio Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.37 1.58 1.33 1.40 1.74

Takeda Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.44 1.37 1.45 1.73 1.49

TAK vs ZTS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takeda Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


TAK
72GF Score
Takeda Pharmaceutical Co Ltd TAK
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Takeda Pharmaceutical Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Takeda Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Takeda Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.385/113.6000*113.6000
=2.385

Current CPI (Jun. 2026) = 113.6000.

Takeda Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 2.598 98.000 3.012
201612 2.709 98.400 3.127
201703 2.347 98.100 2.718
201706 2.568 98.500 2.962
201709 2.483 98.800 2.855
201712 2.749 99.400 3.142
201803 2.369 99.200 2.713
201806 2.621 99.200 3.001
201809 2.454 99.900 2.791
201812 2.808 99.700 3.199
201903 2.094 99.700 2.386
201906 2.476 99.800 2.818
201909 2.418 100.100 2.744
201912 2.537 100.500 2.868
202003 2.209 100.300 2.502
202006 2.380 99.900 2.706
202009 2.362 99.900 2.686
202012 2.540 99.300 2.906
202103 2.306 99.900 2.622
202106 2.756 99.500 3.147
202109 2.428 100.100 2.755
202112 2.516 100.100 2.855
202203 2.416 101.100 2.715
202206 2.414 101.800 2.694
202209 2.317 103.100 2.553
202212 2.468 104.100 2.693
202303 2.238 104.400 2.435
202306 2.462 105.200 2.659
202309 2.305 106.200 2.466
202312 2.370 106.800 2.521
202403 2.255 107.200 2.390
202406 2.440 108.200 2.562
202409 2.447 108.900 2.553
202412 2.301 110.700 2.361
202503 2.189 111.100 2.238
202506 2.410 111.700 2.451
202509 2.389 112.000 2.423
202512 2.413 113.000 2.426
202603 2.208 112.700 2.226
202606 2.385 113.600 2.385

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Takeda Pharmaceutical Co (TAK) Overvalued in 2026?

Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued. The current stock price of $18.91 is trading 34.1% above its estimated GF Value™ of $14.10. GuruFocus considers Takeda Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for TAK:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $14.10 vs. price of $18.91 (34.1% above fair value)
  • GF Score™: 72/100 with 10 warning signs

No single metric tells the full story. See the TAK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Takeda Pharmaceutical Co Business Description

Address 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
72GF Score

Get the complete analysis for TAK

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.91
Price
$14.10
GF Value